The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur).
 
Paul Romesser
Employment - Memorial Sloan-Kettering Cancer Center
Consulting or Advisory Role - EMD Serono; Faeth Therapeutics; Natera
Research Funding - X-RAD Therapeutics (Inst)
(OPTIONAL) Uncompensated Relationships - Anal Cancer Foundation; HPV Alliance
 
Eric Miller
Other Relationship - NCCN
 
Qian Shi
Honoraria - Chugai Pharma
Consulting or Advisory Role - Hoosier Cancer Research Network; Kronos Bio; Mirati Therapeutics; Regeneron; Yiviva
Research Funding - BMS (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
Jesse Dixon
Consulting or Advisory Role - ARTIDIS
 
Sepideh Gholami
Consulting or Advisory Role - Alphasights; Delcath Systems; Iota
 
Sarah White
Consulting or Advisory Role - AstraZeneca; Cook Medical; Guerbet; Histosonics; TriSalus Life Sciences
Speakers' Bureau - Penumbra; Penumbra; Varian Medical Systems
Research Funding - Guerbet (Inst)
Travel, Accommodations, Expenses - Cook Medical
 
Christina Wu
Honoraria - Cancer Treament Centers of America; Medscape
Consulting or Advisory Role - Daiichi Sankyo/Lilly; Exelixis; Natera; Natera; Nova Research Company; Pfizer; Seagen
Research Funding - HUTCHMED; Pfizer; Sirnaomics (Inst); Sumitomo Pharma (Inst)
 
Christopher Goulet
No Relationships to Disclose
 
Kyung-Wook Jee
No Relationships to Disclose
 
Chadwick Wright
No Relationships to Disclose
 
Rona Yaeger
Consulting or Advisory Role - Loxo@Lilly; Mirati Therapeutics; Revolution Medicines
Research Funding - Boehringer Ingelheim (Inst); Boundless Bio (Inst); Daiichi Sankyo/UCB Japan (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
Ardaman Shergill
Honoraria - ASCO; Cholangiocarcinoma Foundation; cholangiocarcinoma summit; Colon Cancer Alliance; Curio Science; oklahoma society of clinical oncology; OncLive/MJH Life Sciences; saint joseph hospital Chicago
Consulting or Advisory Role - Catalyst Pharmaceuticals; Guardant Health; KLJ Associates; Merus; Pfizer; Pfizer; Triptych Health Partners
Research Funding - Astellas Pharma (Inst); BMS (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); Macrogenics (Inst); Merck (Inst); Oncologie (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TP Therapeutics (Inst); verastem (Inst)
Travel, Accommodations, Expenses - colon cancer alliance; Takeda
 
Theodore Hong
Stock and Other Ownership Interests - PanTher Therapeutics
Consulting or Advisory Role - Boston Scientific; Merck; NextCure; Novocure; Syndax; Synthetic Biologics
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); IntraOp (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst)
 
Thomas George
Consulting or Advisory Role - Arbele; Avammune Therapeutics; BillionToOne; Exact Sciences; KAHR Medical; Nihon Medi-Physics; Summit Therapeutics
Research Funding - Amal Therapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BillionToOne (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Elicio Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); OncoC4 (Inst); Regeneron (Inst); Seagen (Inst)
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); Revolution Medicines; SERVIER (I); Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Revolution Medicines (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
Jeffrey Meyerhardt
Employment - Dana-Farber Cancer Institute; Newton Wellesley Hospital (I)
Research Funding - Boston Biomedical (Inst)
 
Kathryn Hitchcock
Research Funding - Merck; Naveris; Novartis
Patents, Royalties, Other Intellectual Property - Provisional patent 63672036 Filing Date: 07-16-2024 A device for delivering total skin electron beam therapy.
Other Relationship - Elekta; Medtronic
(OPTIONAL) Uncompensated Relationships - MVision; Philips Healthcare